APOLLO HOSPITALS ENTERPRISE LIMITED

CIN : L85110TN1979PLC008035

10th February 2026

The Secretary,
Bombay Stock Exchange Ltd (BSE)
Phiroze Jheejheebhoy Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code – 508869
ISIN INE437A01024

The Secretary,
National Stock Exchange,
Exchange Plaza, 5th Floor
Plot No.C/1, 'G' Block
Bandra – Kurla Complex
Bandra (E)
Mumbai – 400 051.
Scrip Code–
APOLLOHOSP
ISIN INE437A01024

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for three and nine months ended December 31, 2025.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website www.apollohospitals.com.

Kindly note of the same.

Thanking You,

Yours faithfully,
For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN
Sr. VICE PRESIDENT – FINANCE
AND COMPANY SECRETARY

APOLLO HOSPITALS ENTERPRISE LIMITED CHENNAI

SANKARANARAYANAN MUTHU KRISHNAN
Digitally signed by SANKARANARAYANAN MUTHU KRISHNAN
Date: 2026.02.10 18:18:53 +05'30'

IS/ISO 9001 : 2000

Regd. Office :
19, Bishop Gardens,
Raja Annamalaipuram,
Chennai - 600 028.

General Office :
"Ali Towers" III Floor,
#55, Greams Road,
Chennai - 600 006.

Tel : 044 - 28290956 / 3896 / 6681
Telefax : 044 - 2829 0956
Email : investor.relations@apollohospitals.com
Website : www.apollohospitals.com

Apollo Hospitals Enterprise Limited

Earnings Update Q3 FY26

Disclaimer

The information contained in this presentation is provided by Apollo Hospitals Enterprise Limited (the "Company") to you solely for your reference. This document is being given solely for your information and for your use and may not be retained by you and neither this presentation nor any part thereof may be (i) used or relied upon by any other party or for any other purpose; (ii) copied, photocopied, duplicated or otherwise reproduced in any form or by any means; or (iii) redistributed, passed on or otherwise disseminated, to any other person without the prior written consent of the Company. Although care has been taken to ensure that the information in this presentation is accurate, and that the opinions expressed are fair and reasonable, the information is subject to change without notice, its accuracy is not guaranteed and has not been independently verified. No representation, warranty, guarantee or undertaking (express or implied) is made as to, and no reliance should be placed on, the accuracy, completeness or correctness of any information, including any projections, estimates, targets and opinions, contained herein, and accordingly, none of the Company, its advisors, representatives or any of its directors assumes any responsibility or liability for, the accuracy or completeness of, or any errors or omissions in, any information or opinions contained herein. None of the Company, its advisors, representatives and its directors, officers, employees or affiliates nor any other person accepts any responsibility or liability (whether arising in tort, contract or otherwise) whatsoever for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise arising in connection therewith, and makes no representation or warranty, express or implied, for the contents of this presentation including its accuracy, fairness, completeness or verification or for any other statement made or purported to be made by any of them, or on behalf of them, and nothing in this presentation or at this presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future.

The statements contained in this document speak only as at the date as of which they are made, and the Company expressly disclaims any obligation or undertaking to supplement, amend or disseminate any updates or revisions to any statements contained herein to reflect any change in events, conditions or circumstances on which any such statements are based. By preparing this presentation, none of the Company, its management, and their respective advisers undertakes any obligation to provide the recipient with access to any additional information or to update this presentation or any additional information or to correct any inaccuracies in any such information which may become apparent. This document does not constitute or form part of and should not be construed as an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company or its subsidiaries or affiliates in any jurisdiction or as an inducement to enter into investment activity. No part of this document, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company. This document is not financial, legal, tax or other product advice. Any person/ party intending to provide finance/ invest in the Company shall do so after seeking their own professional advice and after carrying out their own due diligence procedure to ensure that they are making an informed decision.

This presentation contains statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers and information currently available with them including with respect to the consolidated results of operations and financial condition, and future events and plans of the Company. These statements can be recognized by the use of words such as "expects", "plans", "will", "estimates", "intends" or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. Neither the Company nor its affiliates or advisors or representatives guarantees that the assumptions underlying such forward-looking statements are free from errors nor do they accept any responsibility for either the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You are cautioned not to place undue reliance on these forward looking statements, which are based on the current view of the management of the Company on future events. No assurance can be given that future events will occur, or that assumptions are correct. Neither the Company nor its advisors or representatives assume any responsibility to amend, modify or revise any forward-looking statements, on the basis of any subsequent developments, information or events, or otherwise. Certain numbers in these presentations and materials have been subject to routine rounding off and accordingly figures shown as total in tables and diagrams may not be an arithmetic aggregation of the figures that precede them.

This presentation has not been approved and will not or may not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange in India. This presentation does not purport to be a complete description of the markets conditions or developments referred to in the material. This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose.

The distribution of these materials in certain jurisdictions may be restricted by law and persons into whose possession these materials comes should inform themselves about and observe any such restrictions.

This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This presentation is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This presentation is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Chennai, India, and no other courts, shall have jurisdiction over the same.

Content

Financial Performance Snapshot Q3FY26

(in ₹ Mio)

		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT	Margin	Growth YoY(%)
Healthcare Services		31,832	14%	7,898	24.8%	18%	4,219	13.3%	21%
Apollo HealthCo	Offline PD ^	25,114	21%	1,954	7.8%	23%			
	Online PD^ & 24|7	3,160	15%	(675)	Vs (1,027) in Q3 FY25				
	Total HealthCo	28,274	20%	1,279	4.5%		866	3.1%	170%
AHLL		4,668	20%	476	10.2%	39%	(62)		
Consolidated		64,774	17%	9,653	14.9%	27%	5,023	7.8%	35%

^PD:- Pharmacy Distribution

Financial Performance Snapshot YTD Dec 25

(in ₹ Mio)

		Revenue	Growth YoY(%)	EBITDA(Post Ind AS)	Margin	Growth YoY(%)	PAT		Growth YoY(%)
Healthcare Services		92,874	12%	22,886	24.6%	14%	12,160	13.1%	17%
Apollo HealthCo	Offline PD ^	70,095	18%	5,436	7.8%	21%			
Apollo HealthCo	Online PD^ & 24|7	9,504	21%	(2,117)	Vs (3,196) in YTD Dec24				
Apollo HealthCo	Total HealthCo	79,599	19%	3,319	4.2%		2,166	2.7%	
AHLL		13,758	19%	1,379	10%	29%	(202)		
Consolidated		186,230	15%	27,584	14.8%	22%	14,123	7.6%	34%

^PD:- Pharmacy Distribution

Largest Pan India Hospital Chain



Overseas (Managed)
Bahrain : 1
Bangladesh: 1

	Hospitals	Capacity Census Beds[1]	Operational Census Beds
Overall Total	76	10,325	9,561
Owned Hospitals	47	8,836	8,072
Managed Hospitals	6	790	790
Day Surgery & Cradle (AHLL)	23	699	699

[1]Capacity beds include only census capacity beds and doesn't include emergency, daycare beds, recovery room, dialysis, endoscopy etc.

Healthcare Services Q3 FY26 Snapshot

157,777 In-patients 4%

₹ 180,917 Avg Revenue per IP Patient 11%

67% Occupancy

Revenue ₹ 31,832 Mio 14%

EBITDA ₹ 7,898 Mio 18%

Margin 24.8%

AHLL: Retail Health

Apollo Health & Lifestyle Ltd

Out-of-Hospital care

- Outpatient Clinics
- Diagnostics
- Day Surgery centers
- Single Specialty Facilities :- Dialysis, Sugar and Dental

Organizing the unorganized

- Pathology – Organized chains represent only ~30%
- Mother and Child, Specialized Surgical Centers
- IVF Centers

Significant **opportunity to grow** the primary care and diagnostics businesses Plays a vital role in last-mile care delivery, and in ensuring continuum of care for the consumer

AHLL Q3 FY26 Snapshot

2,457 Diagnostics Centers

308 Clinics

162 Dialysis Centers

265 Dental Centers

Revenue	₹ 4,668 Mio	20%
EBITDA	₹ 476 Mio	39%
Margin	10.2%	

AHL| India's Largest Omni-channel Healthcare Platform

Apollo HealthCo Ltd



Apollo 24|7

Unmatched Size

- **46 Mn.+** Registered Users – **9.5 Lacs** Daily Active Users

Industry-leading Growth at scale

- Platform GMV: INR 525 Cr. in Q3FY26, growth of 28% over Q3 FY25

Full stack digital healthcare platform

- First-in-class AI enabled technologies including India's first Clinical Intelligence Engine

Offline Pharmacy Distribution

- Serving 7,113 Operating Stores as on 31st Dec 2025.

Apollo Telehealth*

- Provides **comprehensive remote healthcare services**.
- Offers **specialized telehealth solutions** like **24/7 Tele-Emergency** and **Tele-Consultancy**.
- Expands access to **healthcare in distant regions**, improving quality of life.
- Operates and maintains Mobile Medical Units/ Mobile Health Units, Patient Facilitation Centres, Digital Dispensaries, and is also engaged in organizing Screening Camps and development of Diagnostic Centres for setting up healthcare awareness programs

*Division of AHEL

Health Co Q3 FY26 Snapshot

7,113 Outlets

~15.5% Omni Private label / Generic sales

Revenue	₹ 28,274 Mio	20%
EBITDA	₹ 2,521 Mio (excl 24|7 operating cost & ESOP)	28%
Margin	8.9%	

- Virtual Doctor Consultation
- Online Booking : Hospitals & Diagnostics
- Online Medicine delivery
- Health Insurance
- Patient e-health records
- Condition management

Clinical Updates and New Initiatives

Hospitals

- Apollo Children's Hospital, Chennai, achieved a significant milestone by treating a 13-month-old with Spinal Muscular Atrophy (Type 1) using gene therapy. Within one month, the child showed notable gains in motor control, vocalisation and feeding ability outcomes absent before therapy, showcasing Apollo's ability to translate cutting-edge science into life-changing results.
- Apollo Spectra Hospital, Delhi launched an advanced multi-robot surgery centre equipped with cutting-edge robotic systems and personalized 3D surgical planning.
- Apollo launched a dedicated Centre of Excellence for Parkinson's & DBS care in Chennai.

AHLL

- Test-menu expansion to cover CLL/ALL leukemia panel by FISH, chromosomal microarray for amniotic fluid (prenatal), ultra-high-resolution chromosomal microarray for assessment of consanguinity, Myeloid Panel – DNA & RNA (Comprehensive), MLPA for BRCA1 & BRCA2, MLPA for Complement Regulating Factors (CRFs) & Atypical Hemolytic Uremic Syndrome (aHUS), Xpert MTB reflex test, IGRA Plus and NGS based HLA typing
- AI-based dental radiology tool implemented across clinics to support X-ray/RVG analysis for improving diagnostic accuracy & clinical decision-making through standardized AI insights
- Organized 3rd National Cradle Conference in New Delhi - 550+ delegates and 150 distinguished faculty members collaborated on the latest advancements in maternity, gynecology, neonatology, pediatrics, and fertility.

Apollo HealthCo

- New User Acquisition driven by an omni-channel strategy, with marketing spend significantly lower than last year and similar to the previous quarter.
- Boosted Diagnostic GMV by expanding into 18 new cities and introducing new channels such as pharmacy stores.
- Deeper Penetration in hospitals through JMC offerings and focus on multi specialities coverage
- Expanded the Insurance business across brands, products, cities, along with network growth driven by recruitment and tech enablement.
- Collaboration with TOI for a pan India print and digital rollout of the Ask Apollo QR led journey (to ask health related questions)

Consolidated Financials

Consolidated Financials Q3FY26

(₹ mio)

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
Q3FY26	Total Revenues	31,832	4,668	28,274	64,774
	EBITDA (Pre 24|7 Cost)	7,898	476	2,521	10,895
	margin (%)	24.8%	10.2%	8.9%	16.8%
	24/7 Operating Cost			(859)	(859)
	ESOP(Non Cash expense)			(383)	(383)
	EBITDA	7,898	476	1,279	9,653
	margin (%)	24.8%	10.2%	4.5%	14.9%
	EBIT	6,265	117	1,079	7,461
	margin (%)	19.7%	2.5%	3.8%	11.5%
	PBT	6,004	(52)	868	6,820
	margin (%)	18.9%	-	3.1%	10.5%
	PAT (Reported)	4,219	(62)	866	5,023
	Exceptional Item#	(124)		(68)	(192)
	PAT (excl Exceptional item)	4,343	(62)	934	5,215
Q3FY25	Total Revenues	27,850	3,895	23,524	55,269
	EBITDA (Pre 24|7 Cost)	6,706	342	1,972	9,020
	margin (%)	24.1%	8.8%	8.4%	16.3%
	24/7 Operating Cost			(1,137)	(1,137)
	ESOP(Non Cash expense)			(268)	(268)
	EBITDA	6,706	342	566	7,615
	margin (%)	24.1%	8.8%	2.4%	13.8%
	EBIT	5,296	37	436	5,769
	margin (%)	19.0%	1.0%	1.9%	10.4%
	PBT	5,132	(90)	321	5,362
	margin (%)	18.4%	-	1.4%	9.7%
	PAT (Reported)	3,483	(80)	321	3,723
YOY Growth					
Revenue		14%	20%	20%	17%
EBITDA		18%	39%	126%	27%
PAT		21%	-	170%	35%

- Overall **Consolidated Revenue grew by 17% to ₹ 64,774 mio.**
- EBITDA grew by 27% to **₹ 9,653 mio.**
- Consolidated PAT grew by 35% **to ₹ 5,023 mio.**

#**Exceptional Item:** The New Labour Code effective from November 21, 2025, has necessitated a provision of ₹192 million increase in gratuity and leave liabilities

Consolidated Financials YTD Dec25

(₹ mio)

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
YTD Dec25	**Total Revenues**	**92,874**	**13,758**	**79,599**	**186,230**
	EBITDA (Pre 24|7 Cost)	**22,886**	**1,379**	**7,027**	**31,291**
	margin (%)	**24.6%**	**10.0%**	**8.8%**	**16.8%**
	24/7 Operating Cost			(2,757)	(2,757)
	ESOP(Non Cash expense)			(951)	(951)
	EBITDA	**22,886**	**1,379**	**3,319**	**27,584**
	margin (%)	**24.6%**	**10.0%**	**4.2%**	**14.8%**
	EBIT	18,112	324	2,631	21,066
	margin (%)	19.5%	2.4%	3.3%	11.3%
	PBT	17,430	(210)	2,174	19,394
	margin (%)	18.8%	-	2.7%	10.4%
	PAT (Reported)	12,160	**(202)**	**2,166**	**14,123**
	Exceptional Item#	(124)	-	(68)	(192)
	PAT (excl Exceptional item)	**12,284**	**(202)**	**2,234**	**14,315**
YTD Dec24	**Total Revenues**	**83,255**	**11,596**	**67,167**	**162,018**
	EBITDA (Pre 24|7 Cost)	**20,144**	**1,065**	**5,567**	**26,775**
	margin (%)	**24.2%**	**9.2%**	**8.3%**	**16.5%**
	24/7 Operating Cost			(3,634)	(3,634)
	ESOP(Non Cash expense)			(621)	(621)
	EBITDA	**20,144**	**1,065**	**1,312**	**22,521**
	margin (%)	**24.2%**	**9.2%**	**2.0%**	**13.9%**
	EBIT	15,977	181	897	17,056
	margin (%)	19.2%	1.6%	1.3%	10.5%
	PBT	15,122	(268)	382	15,236
	margin (%)	18.2%	-	0.6%	9.4%
	PAT (Reported)	**10,409**	**(228)**	**382**	**10,563**
YOY Growth					
Revenue		12%	19%	19%	15%
EBITDA		14%	29%	-	22%
PAT		17%	-	-	34%

- Overall **Consolidated Revenue grew by 15% to ₹ 186,230 mio.**
- EBITDA grew by 22% to **₹ 27,584 mio.**
- Consolidated PAT grew by 34% **to ₹ 14,123 mio.**

	HCS	Health Co	AHLL
Gross Debt	21,617	4,072	2,924
Cash & Cash Equivalents*	30,066	408	1,136
Net Debt	-8,449	3,664	1,788

*Includes investments in Liquid funds and FDs of ₹ 25,568 mio.

Consol Gross Debt	28,614
Consol Net Debt	-2,996

#**Exceptional Item:** The New Labour Code effective from November 21, 2025, has necessitated a provision of ₹192 million increase in gratuity and leave liabilities

Healthcare Services

Hospitals

Healthcare Services Financials

(₹ mio)

₹ Mio	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
No of Hospitals	47	45		47	45	
Operating beds	8,072	7,996	1%	8,072	7,996	1%
Occupancy	67%	68%		67%	69%	
IP Discharges	157,777	150,986	4%	472,331	457,816	3%
ALOS	3.16	3.29	-4%	3.15	3.33	-5%
Avg revenue per In Patient (₹)	**180,917**	**162,957**	**11%**	**175,499**	**160,197**	**10%**
Revenue	**31,832**	**27,850**	**14%**	**92,874**	**83,255**	**12%**
EBITDA (Post Ind AS 116)	**7,898**	**6,706**	**18%**	**22,886**	**20,144**	**14%**
margin (%)	**24.8%**	**24.1%**	**73 bps**	**24.6%**	**24.2%**	**45 bps**
EBIT	**6,265**	**5,296**	**18%**	**18,112**	**15,977**	**13%**
margin (%)	19.7%	19.0%	67 bps	19.5%	19.2%	31 bps
PBT	6,004	5,132	17%	17,430	15,122	15%
PAT	**4,219**	**3,483**	**21%**	**12,160**	**10,409**	**17%**
Margin	13.3%	12.5%	75 bps	13.1%	12.5%	59 bps

- Healthcare Services Revenue grew by 14% in Q3FY26 (Inpatient Volume grew by 4% ; Price of 3% and case mix of 7%)
- CONGO-T :- Volume grew by 6% while revenue grew by 16% in Q3FY26 driven by clinical intensity.
- Average Revenue per In patient grew by **11% to ₹180,917 in Q3FY26**

Capital employed (ROCE – YTD Dec25)	₹ 81,769	ROCE 29.5%

* capital employed excludes CWIP of ₹ 11,405 mio toward new projects under development

Inpatients Revenue Mix YTD Dec25





* Oncology includes Radiotherapy and Chemotherapy

Healthcare Services: Expansion Plan

Operationalized in Q3FY26 :- Pune 75 beds ; Defence Colony 30 beds.

To add 4,400 capacity beds ~3,600 census beds over the next 5 years

Location	Nature	Total Beds	Census Beds	Project Cost (in Crs)
Expected commissioning : FY26 -FY27				
Pune (Phase 1 & Phase 2)#	Hospital Asset Acquisition	384	305	₹ 665
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220	₹ 310
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹ 550
Gurgaon, NCR	Hospital Asset Acquisition	480	400	₹ 1,210
Sarjapur-1	Acquisition - Leased facility	180	150	₹ 300
Jubilee Hills (Expansion)	Brownfield	100	80	₹ 230
Secunderabad (Expansion)	Brownfield	100	80	₹ 70
Malleswaram & Mysore Expansion	Brownfield	140	125	₹ 170
Expected commissioning : FY26 -FY27		**2,029**	**1,660**	**₹ 3,505**
Expected commissioning :FY29-FY30				
Worli, Mumbai	Greenfield	575	500	₹ 1,315
Sarjapur-2	Greenfield	500	400	₹ 944
OMR, Chennai	Greenfield	600	500	₹ 945
Varanasi, U.P	Greenfield	400	300	₹ 640
Lucknow (Expansion), U.P	Brownfield	200	160	₹ 320
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110	₹ 570
Expected commissioning : FY29-FY30		**2,415**	**1,970**	**₹ 4,734**
Grand Total		**4,444**	**3,630**	**8,239**

#Beds operationalized in Q3FY26: Pune – 75 beds

Continue to evaluate bolt-on acquisitions in select Tier -1 cities & Metros

Total Project Cost of ~₹ 8,200crs with Balance to be spent of ~₹5,400crs.

Current Beds (Total Census) – Q3FY26

9,561

Includes Owned, Managed and AHLL

+3,555

Post Expansion

~13,100

Healthcare Services: Expansion Plan

Total Project Cost of ~₹ 8,200crs with Balance to be spent of ~₹5,400crs.

$ Expected Commissioning: FY26-FY27
# Expected Commissioning: FY29-FY30
TB :- Total Beds
CB :- Census Beds

Greenfield
Hospital Asset Acquisition
Acquisition – Leased Facility
Brownfield



$ Gurgaon, NCR
TB:- 480 CB:-400

$ Defence Colony, Delhi
TB:- 42 CB:-27 (Asset Light)
*Operationalized in Q3FY26

 # Lucknow(expansion),UP TB:-200 CB:-160
 # Varanasi, UP TB:- 400 CB:-300

$ Sonarpur, Kolkata
TB:- 270 CB:- 220

 # Worli, Mumbai TB:-575 CB:-500

$ Jubilee Hills expansion TB:- 100 CB:-80
$ Secunderabad expansion TB:-100 CB:-80
 # Comprehensive Cancer Care + Proton TB:-140 CB:-110

$ Pune
TB:- 384 CB:-305
*Partly Operationalized in Q3FY26

$ Gachibowli, Hyderabad
TB:- 375 CB:- 300 (Asset light)

$ Sarjapur-1 TB:- 180 CB:-150 (Lease Facility)
 # Sarjapur-2 TB:- 500 CB:-400 (Greenfield)
$ Malleswaram & Mysore TB:- 140 CB:-125
(Brownfield Expansion)

 # OMR, Chennai TB:-600 CB:-500

Healthcare Services : Operational Snapshot

Metros: Chennai, Hyderabad, Bangalore, Mumbai, Kolkata and Delhi

Non Metros (includes Tier1 & Tier2 cities) Ahmedabad, Bhubaneshwar, Lucknow, Indore, Guwahati, Madurai, Trichy, Nellore,Vizag, Kakinada, Mysore, Nashik, Pune, Bilaspur, Rourkela, Karimnagar, Karur and Karaikudi.

YTD Dec25	6 Metros	Non Metros
Operating Beds	4,581	3,491
Occupancy	71%	62%
ARPP -IP^	208,477	126,379
ROCE	31%	24%

^Avg revenue per In Patient

	Pan India					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	8,072	7,996	1.0%	8,072	7,996	1.0%
Bed Occupancy Rate (%)	67%	68%		67%	69%	
Inpatient volume	157,777	150,986	4.5%	472,331	457,816	3.2%
Outpatient volume(1)	561,427	561,652	0.0%	1,747,409	1,672,573	4.5%
Inpatient ALOS (days)	3.16	3.29	-4.1%	3.15	3.33	-5.2%
Total Net Revenue (₹ mio)(2)	34,781	30,315	14.7%	101,837	91,030	11.9%
Avg revenue per In Patient	180,917	162,957	11.0%	175,499	160,197	9.6%

[1] Outpatient Volume represents New Registrations only |[2]Revenue will differ from the consolidated revenues as this includes Delhi which is not consolidated under Ind AS 116 due to joint control

Tamil Nadu Region

Metro:- Chennai ; Non Metro:- Madurai, Karur, Karaikudi, Trichy and Nellore



	Tamil Nadu Region					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	1,987	2,039	-2.6%	1,987	2,039	-2.6%
Bed Occupancy Rate (%)	68%	64%		66%	64%	
Inpatient volume	41,063	38,561	6.5%	117,941	115,360	2.2%
Outpatient volume[1]	156,724	153,935	1.8%	491,221	459,012	7.0%
Inpatient ALOS (days)	3.04	3.11	-2.5%	3.06	3.12	-1.8%
Total Net Revenue (₹ mio)	10,578	9,253	14.3%	30,813	27,827	10.7%
Avg revenue per In Patient	202,804	186,682	8.6%	203,536	184,546	10.3%

	Current Beds		Post Expansion
Chennai	1,322	+500	1,822
Total	1,987		2,487

YTD Dec25

	Chennai
Operating Beds	1,322
Occupancy	68%
ARPP-IP ^	226,819

	Others
Operating Beds	665
Occupancy	62%
ARPP-IP ^	144,887

Expansion Plan

Location	Nature	Total Beds	Census Beds
OMR, Chennai	Greenfield	600	500

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

AP, Telangana Region

Metro:- Hyderabad; Non Metro:- Karimnagar, Vizag and Kakinada

	AP, Telangana Region					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	1,290	1,240	4.0%	1,290	1,240	4.0%
Bed Occupancy Rate (%)	65%	66%		65%	68%	
Inpatient volume	24,581	22,035	11.6%	73,444	65,842	11.5%
Outpatient volume[1]	72,878	78,971	-7.7%	224,279	229,072	-2.1%
Inpatient ALOS (days)	3.16	3.40	-7.0%	3.16	3.51	-9.9%
Total Net Revenue (₹ mio)	5,498	4,722	16.4%	16,079	13,651	17.8%
Avg revenue per In Patient	191,456	180,753	5.9%	186,445	173,765	7.3%

	Current Beds		Post Expansion
Hyderabad	787	+570	1,357
Total	1,290		1,860

YTD Dec25

	Hyderabad
Operating Beds	787
Occupancy	70%
ARPP-IP ^	195,288

	Others
Operating Beds	503
Occupancy	58%
ARPP-IP ^	165,444

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300
Jubilee Hills (Expansion)	Brownfield	100	80
Secunderabad (Expansion)	Brownfield	100	80
Hyderabad (Comprehensive Cancer Care + Proton)	Brownfield	140	110
Total		715	570

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

Karnataka Region

Metro:- Bangalore; Non Metro:- Mysore

	Karnataka Region					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	781	772	1.2%	781	772	1.2%
Bed Occupancy Rate (%)	67%	71%		68%	75%	
Inpatient volume	16,901	16,991	-0.5%	51,619	53,221	-3.0%
Outpatient volume[1]	78,151	72,056	8.5%	229,023	204,319	12.1%
Inpatient ALOS (days)	2.83	2.97	-4.7%	2.84	2.99	-5.0%
Total Net Revenue (₹ mio)	3,833	3,310	15.8%	11,097	9,870	12.4%
Avg revenue per In Patient	191,388	162,086	18.1%	180,843	155,955	16.0%

	Current Beds		Post Expansion
Bangalore	568	+675	1,243
Total	781		1,456

YTD Dec25

	Bangalore
Operating Beds	568
Occupancy	68%
ARPP-IP ^	197,147

	Others
Operating Beds	213
Occupancy	69%
ARPP-IP ^	131,567

Expansion Plan

Location	Nature	Total Beds	Census Beds
Malleswaram & Mysore Expansion	Brownfield	140	125
Sarjapur-1	Acquisition - Leased facility	180	150
Sarjapur-2	Greenfield	500	400
Total		820	675

[1] Outpatient Volume represents New Registrations only

^Avg revenue per In Patient

Eastern Region

Metro:- Kolkata; Non Metro:- Guwahati, Bhubaneshwar, Bilaspur and Rourkela

	Eastern Region					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	1,820	1,867	-2.5%	1,820	1,867	-2.5%
Bed Occupancy Rate (%)	76%	72%		75%	75%	
Inpatient volume	34,756	32,780	6.0%	104,434	101,156	3.2%
Outpatient volume[1]	109,104	108,894	0.2%	337,643	345,080	-2.2%
Inpatient ALOS (days)	3.66	3.79	-3.3%	3.61	3.82	-5.4%
Total Net Revenue (₹ mio)	6,638	5,770	15.0%	19,511	17,752	9.9%
Avg revenue per In Patient	154,408	140,979	9.5%	149,354	139,279	7.2%

	Current Beds		Post Expansion
Kolkata	736	+220	956
Total	1,820		2,040

YTD Dec25

	Kolkata
Operating Beds	736
Occupancy	80%
ARPP-IP ^	223,460

	Others
Operating Beds	1,084
Occupancy	72%
ARPP-IP ^	102,930

Expansion Plan

Location	Nature	Total Beds	Census Beds
Sonarpur, Kolkata	Hospital Asset Acquisition	270	220

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient ; Kolkata ARPP-IP Grossed up for fee-for-service doctor fees.

Western Region

Metro:- Mumbai; Non Metro:- Nashik, Ahmedabad and Pune

	Western Region					
	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
Operating Beds	963	876	9.9%	963	876	9.9%
Bed Occupancy Rate (%)	51%	57%		52%	59%	
Inpatient volume	13,959	13,109	6.5%	42,031	40,195	4.6%
Outpatient volume(1)	55,694	58,919	-5.5%	164,892	170,957	-3.5%
Inpatient ALOS (days)	3.24	3.50	-7.4%	3.30	3.55	-6.9%
Total Net Revenue (₹ mio)	2,757	2,355	17.1%	7,981	6,970	14.5%
Avg revenue per In Patient	166,264	148,313	12.1%	159,427	142,479	11.9%

	Current Beds		Post Expansion
Mumbai	392	+500	892
Total	963	+730	1,693

YTD Dec25

	Mumbai
Operating Beds	392
Occupancy	67%
ARPP-IP ^	188,970

	Others
Operating Beds	571
Occupancy	43%
ARPP-IP ^	127,683

Expansion Plan

Location	Nature	Total Beds	Census Beds
Pune (Phase 1 & Phase 2)#	Hospital Asset Acquisition	384	305
Worli, Mumbai	Greenfield	575	500
Total		**959**	**805**

#Beds operationalized in Q3FY26: Pune – 75 beds

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

Northern Region

Metro:- Delhi; Non Metro:- Lucknow and Indore

	Q3FY26	Q3FY25	YoY	YTD Dec25	YTD Dec24	YoY
	Northern Region					
Operating Beds	1,231	1,202	2.4%	1,231	1,202	2.4%
Bed Occupancy Rate (%)	67%	74%		69%	74%	
Inpatient volume	26,517	27,510	-3.6%	82,862	82,042	1.0%
Outpatient volume[(1)]	88,876	88,877	0.0%	300,351	264,133	13.7%
Inpatient ALOS (days)	2.85	2.96	-3.8%	2.81	2.97	-5.4%
Total Net Revenue (₹ mio)	5,477	4,905	11.7%	16,357	14,959	9.3%
Avg revenue per In Patient	175,836	152,072	15.6%	167,110	155,038	7.8%

	Current Beds		Post Expansion
Delhi NCR	776	+400	1,176
Total	1,231	+860	2,091

YTD Dec25

	Delhi NCR
Operating Beds	776
Occupancy	71%
ARPP-IP ^	196,171

	Others
Operating Beds	455
Occupancy	65%
ARPP-IP ^	124,661

Expansion Plan

Location	Nature	Total Beds	Census Beds
Gurgaon, NCR	Hospital Asset Acquisition	480	400
Varanasi, U.P	Greenfield	400	300
Lucknow (Expansion), U.P	Brownfield	200	160
Total		**1,080**	**860**

[1] Outpatient Volume represents New Registrations only. ^Avg revenue per In Patient

Diagnostics & Retail Health

Apollo Health & Lifestyle Ltd

Executive Summary

Primary Care

Apollo Dialysis Clinics — Apollo Clinic (Expertise. Closer to you.) — Apollo Sugar Clinics — Apollo Dental

- Core revenues of Primary Care grew by ~18% YoY in 9M FY26
- Preventive Health-checkups Volume grew by ~35% YoY in 9M FY26
- New clinic HIS – One hub – successfully migrated across all clinics
- 3 New Clinics & 16 New Dialysis Centres added in 9M FY26

Diagnostics

Apollo DIAGNOSTICS

- Net addition of 12 Satellite Labs & 239 Collection Centers to the network
- Wellness segment grew by ~32% YoY in 9M FY26 - ~18% of Diagnostics revenue
- Newly launched CRL has processed 5.6 mn tests so far with analytical TAT of 99.9%
  - 35k tests & 15k tubes processed in a single day at its peak capacity
  - 40% increase in retail volumes
- Obtained NABL accreditation for 600+ tests in CRL along with CAP in GRL

Specialty Care

Apollo Spectra Hospitals (Specialists in Surgery) — Apollo Cradle & Children's Hospital — Apollo Fertility

- Spectra: ~5% YoY revenue growth in 9M FY26. Renovation planned for few existing centers in Q4
- Cradle: ~8% YoY revenue growth in 9M FY26
- Fertility: ~5% YoY revenue growth in 9M FY26

AHLL Financials Q3FY 26

(₹ mio)

		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
Q3FY26	Revenue	1,282	1,768	1,843	-225	4,668
	EBITDA	231	191	196	-141	476
	margin (%)	18.0%	10.8%	10.6%	-	10.2%
	EBIT	158	102	-2	-141	117
	PAT	126	95	-141	-169	-90
Q3FY25	Revenue	1,069	1,212	1,724	-110	3,895
	EBITDA	193	116	183	-150	342
	margin (%)	18.1%	9.6%	10.6%	-	8.8%
	EBIT	123	71	-8	-149	37
	PAT	128	66	-151	-161	-117
Growth						
Revenue		20%	46%	7%	-	20%
EBITDA		19%	64%	7%	-	39%

- AHLL revenue & EBITDA grew by 20% & 39% YoY in Q3 FY26 respectively; primarily driven by growth in Diagnostics
- Primary care revenue and EBITDA grew by 20% and 19% respectively YoY in Q3 FY26 due to enhanced corporate & partner outreach
- Specialty care revenue and EBITDA grew by 7% and 7% YoY in Q3 FY26 respectively

	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra	Birthing Centers*	Total
Network	308	79	265	162	2,457	23[1]	34[1]	3,328
Footfalls / Day	2,712	545	225	2,699	23,840	78	114	30,213
Gross ARPP	2,563	3,506	7,027	1,644	724#	108,818	82,525	1,575

Includes BOMA[1] Includes IVF* Without CRL, Diagnostics Gross ARPT is 857#

AHLL Financials YTD Dec25

(₹ mio)

		Primary Care	Diagnostics	Specialty Care	Corporate / Intra Group	AHLL
YTD Dec25	Revenue	3,659	5,119	5,610	-630	13,758
	EBITDA	633	529	644	-428	1,379
	margin (%)	17.3%	10.3%	11.5%	-	10.0%
	EBIT	419	300	41	-436	324
	PAT	318	269	-400	-480	-294
YTD Dec24	Revenue	3,127	3,721	5,257	-510	11,596
	EBITDA	576	407	576	-494	1,065
	margin (%)	18.4%	10.9%	11.0%	-	9.2%
	EBIT	363	285	24	-490	181
	PAT	291	266	-207	-681	-331
Growth						
Revenue		17%	38%	7%	-	19%
EBITDA		10%	30%	12%	-	29%

- AHLL revenue & EBITDA grew by 19% & 29% YoY in 9M FY26 respectively; primarily driven by substantial growth in Diagnostics
- Primary care revenue and EBITDA grew by 17% and 10% YoY in 9M FY26 respectively due to enhanced corporate & partner outreach
- Specialty care revenue and EBITDA grew by 7% and 12% YoY in 9M FY26 respectively

	Primary Clinics	Sugar Clinics	Dental Clinics	Dialysis	Diagnostics	Spectra	Birthing Centers*	Total
Network	308	79	265	162	2,457	23[1]	34[1]	3,328
Footfalls / Day	2,679	542	234	2,627	23,065	86	122	33,187
Gross ARPP	2,458	3,368	6,764	1,639	725#	106,987	83,766	1,603

Includes BOMA[1] Includes IVF* Without CRL, Diagnostics Gross ARPT is 848#

Diagnostics : Key Parameters

Gross Revenue (INR Mn)



EBITDA (INR Mn)[1]



Operational footprint (as of Dec 31, 2025)

~360+ Cities presence

110 Labs

2,300+ Collection Centres

3,300+ Pick-up Points (PUPs)

Avg. Footfalls per day & Avg. gross realization per patient (INR)*



Network Growth – Collection Centers



1. *EBITDA post IND AS 116;*

** Footfalls and ARPV for diagnostics represent outpatient / external business*

Digital Health & Pharmacy Distribution
Apollo HealthCo

India's Largest Omni-Channel Healthcare Platform

Apollo 247 Digital Platform

~46 Mn+ Registrations

~13,500+ Doctors

Daily Active Users	9.2 Lakh
Daily Consultations	15,000+
Daily Medicine Orders	~48,500
Daily Sample Collections	~2,600+



- Virtual Doctor Consultation
- Online Booking : Hospitals & Diagnostics
- Online Medicine delivery
- Insurance
- Patient e-health records
- Condition management

Apollo Pharmacy Platform

7,113 Stores

Added – Q3 185

~15.5%

Omni Private label / generics mix - Q3 FY26

Apollo HealthCo Financials Q3FY26

(` mio)

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
Q3FY26	**Total Revenues**	**25,114**	**3,160**	**28,274**
	EBITDA (Pre 24|7 Cost)	**1,954**	**567**	**2,521**
	margin (%)	**7.8%**	**17.9%**	**8.9%**
	24/7 Operating Cost		-859	-859
	ESOP(Non Cash expense)		-383	-383
	EBITDA	**1,954**	**-675**	**1,279**
	margin (%)	**7.8%**	**-**	**4.5%**
	EBIT			1,079
	PBT			868
	PAT (Reported)			**869**
Q3FY25	**Total Revenues**	**20,786**	**2,738**	**23,524**
	EBITDA (Pre 24|7 Cost)	**1,593**	**378**	**1,972**
	margin (%)	**7.7%**	**13.8%**	**8.4%**
	24/7 Operating Cost		-1,137	-1,137
	ESOP(Non Cash expense)		-268	-268
	EBITDA	**1,593**	**-1,027**	**566**
	margin (%)	**7.7%**	**-**	**2.4%**
	EBIT			436
	PBT			321
	PAT (Reported)			**321**
Revenue		21%	15%	20%
EBITDA (Pre 24|7 Cost)		23%	50%	28%

Healthco (Q3' FY26 vs Q3' FY25)

- 20% growth in revenue in Q3' FY26 vs Q3' FY25.
- **3x PAT** in Q3'FY26 (Rs. 869 Mn) vs Q2'FY25 **(**Rs. 321 Mn)
- Lowest Digital cash loss of Rs 292 Mn in Q3'FY26

Digital Operational Metrics :

- Platform GMV **(28% YoY Growth)** : Rs 5,250 Mn in Q3' FY26, over Q3' FY25 (4,106 Mn)
- IP/OP GMV remains neutral @ Rs 1,252 for Q3'FY 26 over previous year.
- Consistent source for new customer acquisition (launch of 19 mins & Omni Acquisition).
- Continuous Improvement in quantitative parameters in Q3' FY26 vs Q3' FY25:
  - 23% YoY growth in Online Pharma Transactions
  - 25% YoY growth in Transacting users

Digital Cash loss* (in Mn)



Healthco Cash profit* (in Mn)



*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

Apollo HealthCo Financials YTD Dec FY26

(₹ mio)

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total HealthCo
YTD Dec25	**Total Revenues**	**70,095**	**9,504**	**79,599**
	EBITDA (Pre 24|7 Cost)	**5,436**	**1,591**	**7,027**
	margin (%)	**7.8%**	**16.7%**	**8.8%**
	24/7 Operating Cost		-2,757	-2,757
	ESOP(Non Cash expense)		-951	-951
	EBITDA	**5,436**	**-2,117**	**3,319**
	margin (%)	**7.8%**	**-**	**4.2%**
	EBIT			2,631
	PBT			2,174
	PAT (Reported)			**2,173**
YTD Dec24	**Total Revenues**	**59,299**	**7,868**	**67,167**
	EBITDA (Pre 24|7 Cost)	**4,508**	**1,059**	**5,567**
	margin (%)	**7.6%**	**13.5%**	**8.3%**
	24/7 Operating Cost		-3,634	-3,634
	ESOP(Non Cash expense)		-621	-621
	EBITDA	**4,508**	**-3,196**	**1,312**
	margin (%)	**7.6%**	**-**	**2.0%**
	EBIT			897
	PBT			382
	PAT (Reported)			**382**
Revenue		18%	21%	19%
EBITDA (Pre 24|7 Cost)		21%	50%	26%





*Cash loss/profit is EBITDA post Ind As excluding ESOP expense

Healthco (YTD Dec' FY26 vs YTD Dec' FY25)

- 19% growth in revenue in YTD Dec' FY26 vs YTD Dec' FY25.
- **YTD Dec'26 'FY26 PAT of** Rs. 2,173 Mn vs Rs. 382 Mn in YTD Dec 'FY25

Apollo Telehealth (under AHEL)

- Generated Revenue of Rs 481 Mn, with a EBITDA loss of Rs 6 mn for YTD Dec' FY26.

Digital Operational Metrics :

- Platform GMV **(26% YoY Growth)** : Rs 15,081 Mn in YTD Dec' 25, over YTD Dec' 24 (11,973 Mn)
- IP/OP GMV @ Rs 4,282Mn for YTD Dec' 25 over YTD Dec' 24 (Rs 3,822 Mn)
- Consistent source for new customer acquisition (launch of 19 mins & Omni Acquisition). New Lob- Insurance started gaining attraction
- Continuous Improvement in quantitative parameters in YTD Dec ' FY26 vs YTD Dec' FY25:
  - 31% YoY growth in Online Pharma Transactions
  - 32% YoY growth in Transacting users

Apollo HealthCo: Composite Scheme as approved by the Board on June 30, 2025

- Proposes to undertake below transactions sequentially, via a scheme of arrangement, subject to requisite corporate and regulatory approvals

Step 1	• Demerger of Omnichannel pharmacy distribution (OCP) and Apollo 24|7 digital platform (shares of AHEL in Apollo Healthco Ltd) & remote telehealth division of AHEL into New Co
Step 2	• Amalgamation of Apollo Healthco Ltd with and into New Co
Step 2	• Amalgamation of Keimed Private Limited with and into New Co

Upon effectiveness of the Scheme (Post Shareholder and NCLT approval),
New Co to become an ‘Indian Owned and Controlled Company’ (IOCC), and apply for listing on stock exchanges

Composite scheme: Shareholding Structure

Shareholder approved Resultant Group Structure in August 2024



Resultant Group Structure Proposed Now (Post all approvals)

- **Automatic listing of New Co**
- **Direct participation of AHEL shareholders in New Co**



** Includes economic interest of AHEL holding of 49% in FHPL; AHEL effective economic interest through FHPL post merger/ demerger process is ~ 2.5%.

Estimated Listing by Q4FY27 post all approvals.

Proforma Combined Financials Metrics| Snapshot YTD Dec 25

(₹ mio)

	FY24	FY25	Q3 FY26: Offline Pharma Distribution	+ Online Pharma Distribution+247	= Total Healthco	+ Keimed	= Combined Q3 FY26	Combined YTD Dec 'FY26
Revenue	137,701	163,772	25,114	3,160	28,274	39,529	50,380	1,42,559
EBITDA,Pre INDAS	9,614	11,180	1,892	561	2,453	1,296	3,749	10,248
EBITDA %	7.0%	6.8%	7.5%	17.7%	8.7%	3.3%	7.4%	7.2%
24/7 Operating cost	-6,186	-4,781	-	-859	-859	-	-859	-2,757
ESOP Non Cash charge	-891	-1,076	-	-383	-383	-	-383	-951
EBITDA, Pre IndAS	2,533	5,322	1,892	-681	1,211	1,296	2,507	6,540
EBITDA %	1.8%	3.2%	7.5%	N.M.	4.3%	3.3%	5.0%	4.6%
Excluding Digital	6.7%	6.4%					6.8%	6.6%

Company expects to achieve INR 250 bn of run rate annualized revenue in Q4 FY27 with 7% EBITDA

Annexure

Basis of Consolidation

AHEL Standalone Hospitals (100% Ownership)	Location
Chennai Main	Chennai
ACI - Chennai	Chennai
Tondiarpet - Chennai	Chennai
FirstMed - Chennai	Chennai
Apollo Children's Hospital	Chennai
Apollo Specialty, Vanagaram	Chennai
ASH Perungudi	Chennai
Women & Child, Shafee Mohammed Road	Chennai
Apollo Proton & Cancer care	Chennai
Madurai	Madurai
Karur	Karur
Karaikudi	Karaikudi
Trichy	Trichy
Nellore	Nellore
Hyderabad	Hyderabad
Bilaspur	Bilaspur
Rourkela	Odisha
Mysore	Mysore
Vizag (old & new)	Vizag
Karim Nagar	Karim Nagar
Bhubaneswar	Bhubaneswar
Jayanagar	Bangalore
Nashik	Nashik
Malleswaram	Bangalore
Navi Mumbai	Mumbai
Pune	Pune
Defence Colony, Delhi	Delhi

Subsidiaries	Location	Description	AHEL Ownership
Material Subs			
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services Platform	99.68%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	68.84%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	71.84%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	74.00%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Biosciences Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Apollo Hospitals Worli LLP	Mumbai	Hospital	90.10%
Health Axis	Hyderabad	Healthcare Technologies and Remote healthcare	69.99%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Apollo Gleneagles PET-CT Pvt Ltd (w.e.f 30th Sep 2025)	Hyderabad	Diagnostics	100.00%
Apollo HealthTech	India	Digital Omni-Channel Healthcare services Platform	100.00%
Associates	**Location**	**Description**	
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre	50.00%
Stemcyte India Therapautics Pvt Ltd	India	Stemcell Banking	37.75%

IND AS - 116 : Impact on P&L and Balance Sheet –YTD Dec25

AHEL Standalone (post IND AS 116)

Balance sheet

Right of use Asset as of 31st Dec, 2025 ↑	13,757
Lease liabilities as of 31st Dec, 2025 ↑	13,593
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) ↓	2,109

Profit & Loss

Revenue	
Other expenses (Lease rent) ↓	905
EBITDA ↑	905
Amortisation ↑	566
EBIT ↑	339
Finance charge ↑	566
PBT ↓	226

AHEL Consolidated (post IND AS 116)

Balance sheet

Right of use Asset as of 31st Dec, 2025 ↑	25,097
Lease liabilities as of 31st Dec, 2025 ↑	26,642
Equity (Transaction impact as on Apr 01, 2019 - Net of Tax) ↓	3,052

Profit & Loss

Revenue	
Other expenses (Lease rent) ↓	2,071
EBITDA ↑	2,071
Amortisation ↑	1,358
EBIT ↑	713
Finance charge ↑	1,224
PBT ↓	511

Thank you